Literature DB >> 16684527

PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3.

Fiona Kerr1, Annika Rickle, Naushaba Nayeem, Sebastian Brandner, Richard F Cowburn, Simon Lovestone.   

Abstract

Deregulation of PTEN/Akt signalling has been recently implicated in the pathogenesis of Alzheimer's disease (AD), but the effects on the molecular processes underlying AD pathology have not yet been fully described. Here we report that overexpression of PTEN reduces tau phosphorylation in CHO cells. This effect was abrogated by mutant PTEN constructs with either a catalytically inactive point mutation (C124S) or with only inactive lipid phosphatase activity (G129E), suggesting an indirect, lipid phosphatase-dependent process. The predominant effects of PTEN on tau appeared to be mediated by reducing ERK1/2 activity, but were independent of Akt, GSK-3, JNK and the tau phosphatases PP1 and PP2A. Our studies provide evidence for an effect of PTEN on the phosphorylation of tau in AD pathogenesis, and provide some insight into the mechanisms through which deregulation of PTEN may contribute towards the progression of tauopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684527     DOI: 10.1016/j.febslet.2006.04.064

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

Review 1.  Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links.

Authors:  D K Sokol; B Maloney; J M Long; B Ray; D K Lahiri
Journal:  Neurology       Date:  2011-04-12       Impact factor: 9.910

Review 2.  Genetic determinants at the interface of cancer and neurodegenerative disease.

Authors:  L G T Morris; S Veeriah; T A Chan
Journal:  Oncogene       Date:  2010-04-26       Impact factor: 9.867

Review 3.  The Role of ERK1/2 Pathway in the Pathophysiology of Alzheimer's Disease: An Overview and Update on New Developments.

Authors:  Mohammad Rafi Khezri; Keyvan Yousefi; Ayda Esmaeili; Morteza Ghasemnejad-Berenji
Journal:  Cell Mol Neurobiol       Date:  2022-01-17       Impact factor: 5.046

4.  Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons.

Authors:  Liviu Aron; Pontus Klein; Thu-Trang Pham; Edgar R Kramer; Wolfgang Wurst; Rüdiger Klein
Journal:  PLoS Biol       Date:  2010-04-06       Impact factor: 8.029

5.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

6.  A comparative study of beta-amyloid peptides Abeta1-42 and Abeta25-35 toxicity in organotypic hippocampal slice cultures.

Authors:  Rudimar Luiz Frozza; Ana Paula Horn; Juliana Bender Hoppe; Fabrício Simão; Daniéli Gerhardt; Ricardo Argenta Comiran; Christianne Gazzana Salbego
Journal:  Neurochem Res       Date:  2008-08-07       Impact factor: 3.996

Review 7.  The rise and fall of insulin signaling in Alzheimer's disease.

Authors:  B Chami; A J Steel; S M De La Monte; Greg T Sutherland
Journal:  Metab Brain Dis       Date:  2016-02-16       Impact factor: 3.584

8.  An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease.

Authors:  Taner Shakir; Ahmed Y Coulibaly; Patrick G Kehoe
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

9.  PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance.

Authors:  Amit Gupta; Chinmoy Sankar Dey
Journal:  Mol Biol Cell       Date:  2012-08-08       Impact factor: 4.138

10.  Unveiling clusters of RNA transcript pairs associated with markers of Alzheimer's disease progression.

Authors:  Ahmed Shamsul Arefin; Luke Mathieson; Daniel Johnstone; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.